BioCentury
ARTICLE | Clinical News

BerGenBio reports Phase II data for bemcentinib plus Keytruda in NSCLC

June 8, 2018 6:52 PM UTC

BerGenBio ASA (OSE:BGBIO) reported data from 15 evaluable patients with advanced non-small cell lung cancer (NSCLC) in the Phase II BGBC008 trial showing that once-daily 200 mg oral bemcentinib (BGB324) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to an overall response rate (ORR) of 20%, including three partial responses, plus nine cases of stable disease. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, international trial is evaluating the combination in about 48 patients with previously treated advanced NSCLC. Last year, BerGenBio partnered with Merck to conduct the trial...